Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma

Peer Review reports

Original Submission
20 Feb 2022	Submitted	Original manuscript
23 May 2022	Reviewed	Reviewer Report
16 Aug 2022	Reviewed	Reviewer Report - Matthew Walton
26 Sep 2022	Author responded	Author comments - Hongchao Li
6 Oct 2022	Author responded	Author comments - Hongchao Li
Resubmission - Version 2
26 Sep 2022	Submitted	Manuscript version 2
Publishing
11 Oct 2022	Editorially accepted
17 Nov 2022	Article published	10.1186/s12913-022-08661-4

Back to article page